en · de · es · fr · pt
aod-9604-notes.peptides6155.com › Wiki › Identity And Molecular Context — Common Mistakes

Identity And Molecular Context — Common Mistakes

By Editorial Desk · published 2026-04-11 · last reviewed 2026-05-12 · Wiki

hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2026-05-12. Where a claim depends on a specific study, the study is described rather than over-claimed.

Identity and Molecular Context

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.

The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.

Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.

Identity and Research Origin

AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.

Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.

Aod-9604 at a glance

PropertyValueNotes
Molecular classSynthetic peptideDerived from a fragment of human growth hormone
Sequence basishGH residues 176-191Commonly described as a 16-amino-acid fragment
AppearanceWhite to off-white powderTypical for lyophilized research peptides
SolubilitySoluble in water or aqueous bufferExact solubility depends on pH and purity
Common synonymsAOD9604; hGH 176-191Spelling and punctuation vary across sources

Identity and Research Context

Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.

Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.

Related pages on this site

Background And Research Context

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.

The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.

In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.

Regulatory and Analytical Context

Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.

In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.

Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.

Background from the literature

Asparagine peptide lyase are one of the seven groups in which proteases, also termed proteolytic enzymes, peptidases, or proteinases, are classified according to their catalytic residue. The catalytic mechanism of the asparagine peptide lyases involves an asparagine residue acting as nucleophile to perform a nucleophilic elimination reaction, rather than hydrolysis, to catalyse the breaking of a peptide bond. The existence of this seventh catalytic type of proteases, in which the peptide bond cleavage occurs by self-processing instead of hydrolysis, was demonstrated with the discovery of the crystal structure of the self-cleaving precursor of the Tsh autotransporter from E. coli.

Nando's (; Afrikaans: [ˈnandœs]) is a South African multinational fast casual restaurant chain that specialises in Portuguese flame-grilled, peri-peri style chicken. The name is derived from a nickname for the male given name Fernando, in reference to one of the company's founders. Founded in Johannesburg in 1987, Nando's operates over 1,200 outlets in 30 countries. Their logo depicts the Rooster of Barcelos, one of Portugal's most common symbols. The company was wholly owned by Dick Enthoven until his death in 2022, and is now owned by his family.

Locals are "Districts"; national convention meets quadrennially; headquarters in Pittsburgh; in 1979 had $120,000,000 in insurance; also sponsored outings, baseball games, etc. While originally for German men and women, by 1979 the Union was open to men and women of all ethnic backgrounds. In 1923 the Union had 54,000 members, 50,000 in 1965, and 37,000 in 1979. Improved Order, Knights of Pythias Independent Order of Red Men North American Swiss Alliance - Founded July 14, 1865, as the Grütli Bund der Vereinigten Staaten von Nord Amerika in Cincinnati. Became Nordamerikanishcher Schweizerbund in July 1911. National convention meets quadrennially, locals are called branches or lodges. Open to Swiss, Swiss descendants, or spouses of Swiss. Membership 2,000 in 1965, 4,000 in 1978 and 3,350 in 1994, about 10 to 15% are social, uninsured members. Periodical originally called Gruetlianer changed to Der Schweizer in 1911. Headquarters in Cleveland in 1979, but it was an "organization on wheels" moving to several places every few years in the late 19th century Schwarzer Ritter, Deutscher Orden - Claimed great antiquity, though in 1899 it was said to have been present in the United States for about 30 years. Active in New York, New Jersey, Pennsylvania, and the District of Columbia. Sons of Hermann United League of America Workmen's Benefit Fund - Founded as the Workmen's Sick and Death Benefit Fund in 1884, this organization was licensed to provide insurance in February 1899. The current name was adopted in 1939. Membership opened to non-Germans in 1976.

Sources: en.wikipedia.org

Further detail

==== The "disorganized crime" and choice theses ==== One of the most important trends to emerge in criminological thinking about OC in recent years is the suggestion that it is not, in a formal sense, "organized" at all. Evidence includes lack of centralized control, absence of formal lines of communication, fragmented organizational structure. It is distinctively disorganized. For example, Seattle's crime network in the 1970s and 80s consisted of groups of businessmen, politicians and of law enforcement officers. They all had links to a national network via Meyer Lansky, who was powerful, but there was no evidence that Lansky or anyone else exercised centralized control over them. While some crime involved well-known criminal hierarchies in the city, criminal activity was not subject to central management by these hierarchies nor by other controlling groups, nor were activities limited to a finite number of objectives. The networks of criminals involved with the crimes did not exhibit organizational cohesion. Too much emphasis had been placed on the Mafia as controlling OC. The Mafia were certainly powerful but they "were part of a heterogeneous underworld, a network characterized by complex webs of relationships." OC groups were violent and aimed at making money but because of the lack of structure and fragmentation of objectives, they were "disorganized". Further studies showed neither bureaucracy nor kinship groups are the primary structure of organized crime; rather, the primary structures were found to lie in partnerships or a series of joint business ventures.

The American cockroach (Periplaneta americana) is the largest species of cockroach routinely found in homes, and often considered a pest. In certain regions of the U.S. it is colloquially known as the waterbug, though it is not a true waterbug since it is not aquatic, nor a Hemipteran. It is also known as the ship cockroach, kakerlac, and Bombay canary. It is often misidentified as a palmetto bug. Despite their name, American cockroaches are native to Africa and the Middle East. They are believed to have been introduced to the Americas only from the 17th century onward as a result of human commercial patterns, including the Atlantic slave trade.

Tube lubrication: The surface of the bar or tube is coated with a drawing lubricant such as phosphate or oil to aid cold drawing. Push pointing: Several inches of the lead ends of the bar or tube are reduced in size by swaging or extruding so that it can pass freely through the drawing die. This is done because the die opening is always smaller in size than the original bar or coil section. Cold drawing, process drawing: In this process, the material is drawn at room temperature. The reduced end of the bar or coil, which is smaller than the die opening, is passed through the die where it enters a gripping device of the drawing machine. The drawing machine pulls ("draws") the remaining unreduced section of the bar or coil through the die. The die reduces the cross section of the bar or coil, shapes its profile, and increases its length. Finished product: The drawn product, which is referred to as "cold drawn" or "cold finished", exhibits a bright or polished finish, increased mechanical properties, improved machining characteristics, and precise and uniform dimensional tolerances. Multi-pass drawing: The cold drawing of complex shapes or profiles may involve the workpiece being drawn multiple times through progressively smaller die openings in order to produce the desired shape and tolerances. Material is generally annealed between each drawing pass to increase its ductility and remove internal stresses produced during the cold working.

Artificial bone can be created from ceramics such as calcium phosphates (e.g. hydroxyapatite and tricalcium phosphate), Bioglass and calcium sulfate; all of which are biologically active to different degrees depending on solubility in the physiological environment. These materials can be doped with growth factors, ions such as strontium or mixed with bone marrow aspirate to increase biological activity. Some authors believe this method is inferior to autogenous bone grafting; however, infection and rejection of the graft is much less of a risk, and the mechanical properties such as Young's modulus are comparable to bone. The presence of elements such as strontium can result in higher bone mineral density and enhanced osteoblast proliferation in vivo.

Sources: en.wikipedia.org

Frequently asked questions

Is AOD-9604 the same as human growth hormone?

No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.

What is the exact length of AOD-9604?

It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.

Does AOD-9604 occur naturally?

It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.

Network